

#6a  
1/31/03



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
JAN 30 2003  
TECH CENTER 1600/2900

In re application of

Docket No: Q64360

Ryuichi MORISHITA , et al.

Appln. No.: 09/856,374

Group Art Unit: 1632

Confirmation No.: 8301

Examiner: Liping Chen

Filed: May 21, 2001

For: GENE THERAPY FOR CEREBROVASCULAR DISORDERS

AMENDMENT UNDER 37 C.F.R. § 1.111

Commissioner for Patents  
Washington, D.C. 20231

Sir:

This Amendment is responsive to the Office Action mailed August 28, 2002. The Examiner set a three month period for the response. Attached hereto and herein incorporated by reference is a Petition for a two-month extension of time, making the due date for response January 28, 2003.

Please amend the above-identified application as follows:

IN THE CLAIMS:

Please cancel claims 10-12, 18 and 21-25 without prejudice or disclaimer.

Please enter the following amended claims:

Q5 1. (Amended) A therapeutic or preventive agent for cerebrovascular disorders, said agent comprising, as an active ingredient, an HGF gene and/or a VEGF gene, wherein said HGF gene and said VEGF gene are in the form of HVJ-liposomes.

Q2 3. (Amended) A therapeutic or preventive agent for reduced blood flow in the brain comprising, as an active ingredient, an HGF gene and/or a VEGF gene, wherein said HGF gene and said VEGF gene are in the form of HVJ-liposomes.